1 ФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава России, Москва, Россия; 2 ФГБУ «Национальный медицинский исследовательский центр им. В.А. Алмазова» Минздрава России, Санкт-Петербург, Россия В основе врожденного гиперинсулинизма (ВГИ) лежит гиперпродукция инсулина β-клетками поджелудочной железы. Из-за высокого риска осложнений хронической гипогликемии у пациентов с ВГИ приоритетной задачей является своевре-менная диагностика заболевания и незамедлительное начало терапии. Выбор тактики лечения во многом зависит от мор-фологической формы заболевания. Клинико-лабораторная картина заболевания, данные УЗИ, МРТ, компьютерной и по-зитронной-эмиссионной томографии (ПЭТ) с [18F]-фтордезоксиглюкозой не позволяют установить морфологическую форму заболевания. Ранее для дифференциальной диагностики применялись стимуляционный тест с кальцием и чрескож-но-чреспеченочный забор крови из ветвей воротной вены, однако эти инвазивные исследования дают недостаточно точ-ные результаты. В настоящий момент дифференциальная диагностика диффузной и фокальной форм ВГИ на предопера-ционном этапе базируется на данных молекулярно-генетической и радионуклидной диагностики (ПЭТ с [18F]-фторДОФА). В статье представлены первые результаты применения ПЭТ с [18F]-фторДОФА у пациентов с ВГИ в России. Радиону-клидное исследование было выполнено 17 пациентам с фармакорезистентным течением ВГИ. В дальнейшем результаты ПЭТ/КТ с [18F]-фторДОФА сопоставлялись с гистологической картиной препаратов поджелудочной железы, полученных интраоперационно («золотой стандарт» дифференциальной диагностики морфологических форм ВГИ). Radionuclide study was performed in 17 patients with pharmacoresistant CHI followed by comparative analysis of the results of 18F-FDG PET/CT and histological picture of intraoperative pancreatic tissue samples, which is known as the gold standard for the differential diagnosis of HI histological forms.
INTRODUCTION
Congenital hyperinsulinism (CHI) is a disease characterized by persistent hypoglycemia due to increased insulin secretion by β-pancreatic cells. CHI is the most common cause of hypoglycemia in young children; the incidence of disease in the population is 1 in 30,000-50,000 live newborns and 1 in 2,500 cases in populations with a high level of consanguinity [1, 2] .
The main clinical manifestations of hypoglycemia in infants during the fi rst months of life are weakness, loss of consciousness, and seizures. Given the high risk of complications in chronic hypoglycemia (psychomotor retardation, epilepsy, blindness), the timely diagnosis and early-onset treatment are required for CHI patients.
Pathogenic mutations in genes encoding ATP-dependent potassium channels (ABCC8, KCNJ11) are the most common cause of CHI [3] . Dysfunction of ATP-dependent K + channels leads to membrane depolarization, increased calcium intake into cells, and, thereby, insulin hypersecretion. Mutations in the GCK, GLUD1, HADH, HNF4a, INSR, and UCP2 genes can also lead to the development of CHI. There are diff use and focal histological forms of CHI, which are associated with genetic abnormalities. For example, the diff use form, which is characterized by excessive production of insulin in all β-cells, is most often associated with homozygous or compound heterozygous mutations in the ABCC8 and KCNJ11 genes. The condition of most patients with diff use CHI is improved upon drug therapy; however, if the therapy fails, subtotal pancreatectomy (resection of 95-98% of the pancreas) is required [4] .
Focal CHI develops sporadically and is associated with a pathological mutation on the paternal allele in the ABCC8 or KCNJ11 genes in combination with a specifi c loss of the maternal allele in the 11p15.15 imprinting region [5] . Insulin hypersecretion in patients with focal CHI occurs in a limited adenomatous region. The medically unresponsive disease is observed in 96.2% of patients with focal CHI [6] . The optimal treatment for theses patients is resection of the lesion with preservation of the remaining intact pancreatic tissue [7] .
Given the diff erences in surgical tactics, a high risk of diabetes due to subtotal pancreatectomy [8] , and the possibility of complete recovery of patients with focal CHI after resection of an adenomatous lesion, the preoperative diff erential diagnosis of a morphological CHI form is extremely important.
The morphological form of medically unresponsive disease can not be identifi ed based only on clinical laboratory fi ndings. A CHI form may be determined using molecular genetic testing. Such techniques as ultrasound, MRI, CT, and [18F]-fl uorodeoxyglucose PET do not enable visualization of an adenomatous lesion. A calcium stimulation test and percutaneous transhepatic blood sampling from the portal vein were previously used to diff erentiate the diagnosis; however, high invasiveness and a low accuracy of these techniques initiated the search for other ways to diagnose the histological form of CHI [9] .
Currently, the most accurate technique for diff erential diagnosis of diff use and focal forms of CHI is [18F]-fl uoroDOPA PET (sensitivity, 89%; specifi city, 98%) [10] . The diagnostic effi cacy of this technique is based on high uptake of [18F]-fl uoroDOPA by β-cells overproducing insulin. During [18F]-fl uoroDOPA PET, the uniformity of radiopharmaceutical (RP) uptake in the pancreatic tissue is visually evaluated, and the pancreatic index (PI) is calculated, whose value is used to diff erentiate between diffuse and focal forms of CHI in the examined patient [11, 12] . According to the international guidelines, [18F]-fl uoroDOPA PET/CT fi ndings are interpreted as diff use CHI at PI of less than 1.30 and as focal CHI at PI of more than 1.50 [13] .
A series of clinical cases
examination standards and patient group description Seventeen CHI patients (11 females and 6 males) underwent [18F]-fl uoroDOPA PET/CT at the Almazov National Medical Research Center. The diagnosis of CHI in all patients was established at the Endocrinology Research Center, based on hypoketotic hypoglycemia that persisted since the fi rst days of life without reducing insulin levels. At the hospital, the patients also underwent molecular genetic testing to identify mutations responsible for the development of the disease. Despite ongoing insulinostatic therapy (diazoxide, somatostatin, glucagon), all patients experienced frequent episodes of hypoglycemia, which indicated the medically unresponsive form of CHI.
The age of children at the time of [18F]-fl uoroDOPA PET/CT examination ranged from 2 months to 2 years 9 months (median, 3.45 months). All patients were under inpatient follow-up before and after the study. According to the international recommendations [13] , pharmacological therapy with insulinostatic agents was discontinued in all patients 48-72 h before [18F]-fl uoroDOPA PET. Normal blood glucose indicators were maintained by intravenous infusion of a glucose solution with glycemic control every 20 min. Given the need for general anesthesia, the patients had a hungry interval of 5 to 6 h; a peripheral intravenous catheter was placed for RP administration. The drug Propofol was used for general anesthesia. The drug dose was calculated based on the patient's body weight. During PET, patients occurred in the supine position and were immobilized. The examination was conducted using a combined Discovery 710 PET/CT system (General Electric). The drug [18F]-fl uoroDOPA was synthesized at the Department of Radiopharmaceutical Agent Production of the Almazov National Medical Research Center.
[18F]-fl uoroDOPA was administered as an intravenous bolus at a dose of 4 MBq per 1 kg body weight. CT was performed in a low-dose mode (40 mA, 80 kV) to correct photon energy absorption. PET data was acquired in a static mode: 10-minute scans were also recorded 10, 30, 40, 50, and 60 min after injection. After study completion, the children were followed-up at the Therapeutic Department.
PET images were evaluated in three planes: axial, frontal and, sagittal, as well as in a 3D reconstruction mode. In the presence of an [18F]-fl uoroDOPA hyperfi xation focus in the pancreas, the pancreatic index was calculated using a 10-minute scan acquired 50-60 min after RP administration: the ratio of the maximum standardized RP uptake index (SUVmax) value in the [18F]-fl uoroDO-PA hyperfi xation focus to the next lower SUVmax value in apparently intact pancreatic parenchyma. In the case of a uniform RP distribution in the pancreatic parenchyma, SUVmax was evaluated in the pancreatic head, body, and tail. According to the PET/CT [18F]-fl uoroDOPA fi ndings, the conclusion on the morphological form of CHI was made based on the visual data and PI index.
After surgery, pancreatic tissue morphology was studied in 16 children. One patient with suspected diff use CHI did no undergo surgical treatment and morphological study due to relatively stable glucose indicators during treatment with a long-acting somatostatin analog and frequent feeding.
Examination findings
According to the molecular genetic analysis, diff use CHI was suggested in 7 children: homozygous, compound heterozygous, and dominant mutations in the ABCC8, KCNJ11, and HNF4α genes were found in these patients (Table 1) . Focal CHI was suspected in 10 patients in whom heterozygous mutations were found on the paternal allele in genes encoding ATP-dependent potassium channels.
On the basis of the [18F]-fl uoroDOPA PET/CT fi ndings, 7 out of 17 patients were diagnosed with diff use CHI, and the remaining 10 patients were diagnosed with focal CHI. Physiological RP uptake was observed in the pancreas, liver, gallbladder, kidneys, and urinary tract. During the study, all children had increased RP uptake in the pancreatic head, which was considered as a norm, given the differences in β-cell density in diff erent parts of the organ.
In patients with focal CHI (n=10), the median PI at the 50th-60th minutes of the examination amounted to 1.64 (1.14-3.51), and a signifi cant increase in local RP uptake on PET images was also visually detected (Fig. 1A) . A single focus of elevated RP uptake was detected in all patients of this group: in the pancreatic head (7 patients); in the body (1 patient); in the tail (1 patient); in one patient, the focus was located between the head and the body of the pancreas. The minimum and maximum scintigraphic size of the detected [18F]-fl uoroDOPA hyperfi xation focus was 1.32 and 22.00 mm, respectively.
In patients with diff use CHI (n=7), the median PI at the 50th-60th minutes of [18F]-fl uoroDOPA PET was 1.15 (1.02-1.42) (Fig. 1B) . Except the pancreas, no other pathological RP uptake localizations were found in the examined patients.
Discussion
the issue of diff erential diagnosis of morphological CHI forms is particularly important in patients with the medically unresponsive disease. The fi rst step in identification of the CHI form is molecular genetic testing due to its informativeness and minimal risks to the patient's health. Despite the fact that a CHI form suggested in our patients based on molecular genetic testing fully coincided with the fi nal histological diagnosis, this method may provide erroneous results. For example, a pathological heterozygous mutation on the paternal allele in patient 12 (Table 1 ) was detected only after repeated molecular genetic testing. Furthermore, according to the international literature, genetic mutations are not detected in 21% of patients with medically unresponsive disease [14] , and diffuse uptake of [18F]-fluoroDOPA in PET occurs in 26-31% of patients with heterozygous mutations on the paternal allele [15, 16] .
[18F]-fl uoroDOPA PET/CT enables more accurate identifi cation of the morphological CHI form and acquisition of visual data. The main calculated parameter in this examination is PI; if its value is less than 1.3, diff use CHI is most likely; if the PI value is more than 1.5, the focal form is most likely. In our study, diff use CHI was suspected in a patient with PI greater than 1.30. This child had increased RP uptake in the pancreatic head region (patient 3, PI=1.42), which may be associated with increased physiological uptake of [18F]-fl uoroDOPA in this area. The absence of pathological mutations in the genes encoding ATP-dependent K + channels also suggested the diff use form of CHI.
Upon [18F]-fl uoroDOPA PET/CT, the focal form of CHI was detected not only in patients with PI of more than 1.50 at the 50th-60th minutes of the examination but also in patients with PI of 1.15 (patient 6), 1.14 (patient 7), and 1.40 (patient 12). This conclusion was based on increased RP uptake in certain pancreatic regions (assessed visually) and the presence of mutations in the paternal ABCC8 and KCNJ11 genes, respectively. We think that the reduced PI is associated with increased RP uptake in the pancreatic head; the ratio of SUVmax in the pathological focus to SUVmax in the head area gave a lower value. In these examples, the ratio of SUVmax in the pathological focus and in the pancreatic tail region (PI) exceeded 1.50. Furthermore, upon calculating PI at the 10th min of examination in patients 6 and 7, this index was 1.60 and 1.83, respectively, which was associated with a smaller SUV value in the pancreatic head region in the specifi ed time in [10, [17] [18] [19] . We suggest conducting [18F]-fl uoroDOPA PET/CT in the following categories of CHI patients: patients with medically unresponsive CHI and suspected focal CHI (inherited from the father or de novo heterozygous mutation in the KCNJ11 or ABCC8 gene); patients with medically unresponsive CHI and without identifi ed pathological mutations in the genes characteristic of CHI; patients with medically unresponsive CHI and the presence of compound heterozygous mutations in the KCNJ11 or ABCC8 gene, as well as in the case of persistent hyperinsulinemic hypoglycemia in children with CHI after partial resection of the pancreas or subtotal pancreatectomy.
Conclusion
Patients with medically unresponsive forms of CHI need a timely diff erential diagnosis of the morphological form of disease, which further enables choosing the approach and extent of surgical intervention. A focus of increased RP uptake in the pancreatic body and head region in patient 7 with focal CHI. PI at the 50th-60th minutes of examination was 1.14, whereas it was 1.6 at the 10th-20th minutes.
A B Fig. 1, B . Results of positron emission tomography with 18F-DOPA: a diffuse form of CHI.
Uniform RP uptake in a patient with diffuse CHI. PI at the 50th-60th minutes of examination was 1.15.
